CA2675291C - Killer ig-like receptor (kir) antibodies, formulations, and uses thereof - Google Patents
Killer ig-like receptor (kir) antibodies, formulations, and uses thereof Download PDFInfo
- Publication number
- CA2675291C CA2675291C CA2675291A CA2675291A CA2675291C CA 2675291 C CA2675291 C CA 2675291C CA 2675291 A CA2675291 A CA 2675291A CA 2675291 A CA2675291 A CA 2675291A CA 2675291 C CA2675291 C CA 2675291C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- kir
- cancer
- formulation
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87996407P | 2007-01-11 | 2007-01-11 | |
| US60/879,964 | 2007-01-11 | ||
| US91152707P | 2007-04-13 | 2007-04-13 | |
| US60/911,527 | 2007-04-13 | ||
| PCT/EP2008/050306 WO2008084106A1 (en) | 2007-01-11 | 2008-01-11 | Anti-kir antibodies, formulations, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2675291A1 CA2675291A1 (en) | 2008-07-17 |
| CA2675291C true CA2675291C (en) | 2017-05-23 |
Family
ID=39144327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2675291A Active CA2675291C (en) | 2007-01-11 | 2008-01-11 | Killer ig-like receptor (kir) antibodies, formulations, and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100189723A1 (https=) |
| EP (2) | EP2109460B1 (https=) |
| JP (3) | JP5478261B2 (https=) |
| CN (2) | CN101578113B (https=) |
| AU (1) | AU2008204433B2 (https=) |
| CA (1) | CA2675291C (https=) |
| ES (2) | ES2627923T3 (https=) |
| WO (1) | WO2008084106A1 (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| ES2393485T3 (es) | 2003-07-02 | 2012-12-21 | Innate Pharma | Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia |
| EP3072522B1 (en) * | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
| PL3604510T3 (pl) | 2009-03-30 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Antidota na inhibitory czynnika xa i sposoby ich stosowania |
| PT2453910T (pt) * | 2009-07-15 | 2016-12-07 | Portola Pharm Inc | Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento |
| CA2815000C (en) * | 2010-10-22 | 2024-05-21 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory t cells programmed to suppress an immune response |
| CN106963947A (zh) * | 2010-11-22 | 2017-07-21 | 伊纳特医药股份有限公司 | Nk细胞调节治疗和用于治疗血液恶性疾病的方法 |
| KR20120093002A (ko) | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
| SG10201603962TA (en) | 2011-05-25 | 2016-07-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
| PL2904011T3 (pl) | 2012-10-02 | 2018-01-31 | Bristol Myers Squibb Co | Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka |
| EP2968538A1 (en) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
| WO2015069785A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| EP3212227B1 (en) | 2014-10-28 | 2020-01-15 | Children's University Hospital Tübingen | Treatment of pediatric bcp-all patients with an anti-kir antibody |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CN107667173A (zh) | 2015-05-06 | 2018-02-06 | 斯尼普技术有限公司 | 改变微生物种群和改善微生物群 |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| CN108350416A (zh) | 2015-11-09 | 2018-07-31 | 百时美施贵宝公司 | 操纵在cho细胞中产生的多肽的品质属性的方法 |
| BR112018017195A2 (pt) * | 2016-02-24 | 2019-01-02 | Children's Hospital Of Eastern Ontario Research Institute Inc. | terapia de combinação de smc para o tratamento do câncer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| JP7542946B2 (ja) | 2016-09-27 | 2024-09-02 | ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム | マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法 |
| CN110072540B (zh) | 2016-10-12 | 2023-06-02 | 得克萨斯州大学系统董事会 | 用于tusc2免疫治疗的方法和组合物 |
| WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| KR102775647B1 (ko) | 2017-03-31 | 2025-03-06 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3768698B1 (en) | 2018-03-19 | 2025-02-12 | MultiVir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| AU2019246043B2 (en) | 2018-03-25 | 2024-07-04 | Snipr Biome Aps. | Treating and preventing microbial infections |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| EP3774911A1 (en) | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| CN112638375A (zh) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | 通过后细胞信号传导因子的调节来增加免疫活性 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| WO2020106983A1 (en) | 2018-11-21 | 2020-05-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer |
| WO2020127965A1 (en) | 2018-12-21 | 2020-06-25 | Onxeo | New conjugated nucleic acid molecules and their uses |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| US20230348854A1 (en) * | 2020-05-08 | 2023-11-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Chimeric antigen receptors (cars) targeting natural killer cells |
| KR20220166837A (ko) * | 2020-06-11 | 2022-12-19 | 난징 바이오흐엥 바이오테크 씨오., 엘티디 | Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2025500922A (ja) | 2021-12-16 | 2025-01-15 | ヴァレリオ・セラピューティクス | 新規のコンジュゲートされた核酸分子及びその使用 |
| EP4493575A1 (en) | 2022-03-18 | 2025-01-22 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| KR20250120305A (ko) | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU707440B2 (en) * | 1994-03-29 | 1999-07-08 | Celltech Therapeutics Limited | Antibodies against E-selectin |
| US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| EP1465720A4 (en) | 2001-12-19 | 2010-05-12 | Biogen Idec Inc | METHODS FOR DETECTING HALF ANTIBODIES BY IMPLEMENTING GEL ELECTROPHORESIS ON INTEGRATED CIRCUITS |
| EP1481010A2 (en) | 2002-02-28 | 2004-12-01 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| ES2393485T3 (es) * | 2003-07-02 | 2012-12-21 | Innate Pharma | Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia |
| SI1639013T1 (sl) * | 2003-07-02 | 2013-01-31 | Innate Pharma | Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji |
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| DK2311873T3 (en) | 2004-01-07 | 2018-11-26 | Novartis Vaccines & Diagnostics Inc | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
| EA009873B1 (ru) * | 2004-02-06 | 2008-04-28 | Элан Фармасьютикалз, Инк. | Способ ингибирования роста опухоли и/или метастатического прогрессирования |
| EP2287195B1 (en) * | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| EP1805931A4 (en) * | 2004-10-29 | 2010-11-10 | Hid Global Corp | MANUFACTURE OF AUTHORIZATION FOR A SAVED CONSUMPTION OF CONSUMPTION |
| CN101103043A (zh) * | 2005-01-06 | 2008-01-09 | 诺和诺德公司 | Kir结合剂和使用其的方法 |
| JP2008538767A (ja) * | 2005-04-22 | 2008-11-06 | ジェネンテック・インコーポレーテッド | Ｃｄ２０抗体による認知症又はアルツハイマー病の治療方法 |
| US8709411B2 (en) * | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
| SG10201603962TA (en) * | 2011-05-25 | 2016-07-28 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
-
2008
- 2008-01-11 US US12/521,105 patent/US20100189723A1/en not_active Abandoned
- 2008-01-11 AU AU2008204433A patent/AU2008204433B2/en not_active Ceased
- 2008-01-11 CA CA2675291A patent/CA2675291C/en active Active
- 2008-01-11 WO PCT/EP2008/050306 patent/WO2008084106A1/en not_active Ceased
- 2008-01-11 JP JP2009545192A patent/JP5478261B2/ja not_active Expired - Fee Related
- 2008-01-11 CN CN200880002001.2A patent/CN101578113B/zh not_active Expired - Fee Related
- 2008-01-11 CN CN201510142726.3A patent/CN105037549B/zh not_active Expired - Fee Related
- 2008-01-11 ES ES13159380.8T patent/ES2627923T3/es active Active
- 2008-01-11 EP EP08707869.7A patent/EP2109460B1/en not_active Not-in-force
- 2008-01-11 ES ES08707869.7T patent/ES2579768T3/es active Active
- 2008-01-11 EP EP13159380.8A patent/EP2604278B1/en not_active Not-in-force
-
2013
- 2013-10-11 JP JP2013213757A patent/JP6223771B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-27 US US14/606,814 patent/US9879082B2/en not_active Expired - Fee Related
- 2015-11-20 JP JP2015227492A patent/JP2016104728A/ja active Pending
-
2017
- 2017-12-20 US US15/849,128 patent/US10815299B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5478261B2 (ja) | 2014-04-23 |
| JP2016104728A (ja) | 2016-06-09 |
| JP2014050393A (ja) | 2014-03-20 |
| EP2109460A1 (en) | 2009-10-21 |
| US20150197569A1 (en) | 2015-07-16 |
| CN105037549A (zh) | 2015-11-11 |
| JP2010515709A (ja) | 2010-05-13 |
| WO2008084106A9 (en) | 2009-09-17 |
| EP2109460B1 (en) | 2016-05-18 |
| WO2008084106A1 (en) | 2008-07-17 |
| US20180208652A1 (en) | 2018-07-26 |
| CN105037549B (zh) | 2018-09-28 |
| ES2579768T3 (es) | 2016-08-16 |
| ES2627923T3 (es) | 2017-08-01 |
| EP2604278A1 (en) | 2013-06-19 |
| US10815299B2 (en) | 2020-10-27 |
| AU2008204433B2 (en) | 2014-03-13 |
| US20100189723A1 (en) | 2010-07-29 |
| EP2604278B1 (en) | 2017-04-12 |
| CA2675291A1 (en) | 2008-07-17 |
| AU2008204433A1 (en) | 2008-07-17 |
| US9879082B2 (en) | 2018-01-30 |
| CN101578113B (zh) | 2015-04-22 |
| CN101578113A (zh) | 2009-11-11 |
| JP6223771B2 (ja) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2675291C (en) | Killer ig-like receptor (kir) antibodies, formulations, and uses thereof | |
| US11840567B2 (en) | Bispecific antibodies with specific binding to CD47 and PD-L1 | |
| DK2552966T3 (en) | ANTIBODIES AGAINST CSF-1R | |
| CN108290953B (zh) | 抗pd-1抗体和组合物 | |
| KR20230125859A (ko) | 암에 대한 조합 요법 | |
| BR112021012299A2 (pt) | Anticorpo anti-pd1 humanizado e uso do mesmo | |
| BR112019021781A2 (pt) | anticorpo monoclonal, célula hospedeira, método para produzir anticorpo, composição farmacêutica, combinação farmacêutica, método para inibir a atividade biológica e método de utilização do anticorpo | |
| TW202319400A (zh) | 用於治療aml之抗體 | |
| US20220332818A1 (en) | Bispecific antibody targeting pd-1 and tim-3 | |
| CN110291105B (zh) | 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗 | |
| AU2013237638B2 (en) | Anti-kir antibodies, formulations, and uses thereof | |
| WO2022018294A1 (en) | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251021 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260223 |